Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 77,398,000	$ 70,542,000
Marketable securities	0	16,784,000
Trade receivables, net	18,717,000	9,811,000
Partnership receivables	1,047,000	1,790,000
Inventory	1,106,000	1,656,000
Clinical trial retainers	706,000	1,181,000
Other prepaid expenses and other current assets	1,757,000	2,972,000
Total current assets	100,731,000	104,736,000
Property and equipment, net	225,000	276,000
Operating lease right-of-use asset	32,000	178,000
Other assets	245,000	151,000
Total assets	101,233,000	105,341,000
Current liabilities:
Accounts payable	5,039,000	2,712,000
Accrued clinical trial costs and contract manufacturing	10,589,000	5,046,000
Accrued compensation and benefits	5,728,000	4,963,000
Other accrued liabilities	9,572,000	5,421,000
Operating lease liability	2,000	11,000
Less loans payable current, net of discount	11,493,000	0
Deferred revenue	0	578,000
Total current liabilities	42,423,000	18,731,000
Loans payable, net of discount	27,185,000	37,960,000
Other liabilities, non-current (Note 6)	2,780,000	2,780,000
Total liabilities	72,388,000	59,471,000
Stockholders’ equity:
Preferred stock, $0.001 par value: 5,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at each of September 30, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value: 80,000 shares authorized at September 30, 2022 and 50,000 at December 31, 2021; 34,621 shares issued and outstanding at September 30, 2022 and 34,475 at December 31, 2021	35,000	34,000
Additional paid-in capital	725,141,000	720,386,000
Accumulated other comprehensive loss	0	(3,000)
Accumulated deficit	(696,331,000)	(674,547,000)
Total stockholders’ equity	28,845,000	45,870,000
Total liabilities and stockholders’ equity	$ 101,233,000	$ 105,341,000